TARDYFERON B9 (ferrous sulfate, folic acid), antianaemic
HAEMATOLOGY - FOCUS
Opinions on drugs -
Posted on
Sep 10 2015
Reason for request
Renewal of inclusion
- TARDYFERON B9 has Marketing Authorisation in the preventive treatment of iron and folic acid deficiencies in pregnant women when an adequate dietary intake cannot be guaranteed.
- Systematic supplementation is not indicated during pregnancy with a combination of iron and folic acid for the prevention of a possible deficiency.
- Only proven iron deficiency needs to be treated with iron and folic acid.
Clinical Benefit
Insufficient |
- |
Therapeutic use
- |
-
English version
Contact Us
Évaluation des médicaments